About heron therapeutics inc. - HRTX
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.
HRTX At a Glance
Heron Therapeutics, Inc.
25 Fenton Main Street
Cary, North Carolina 27511
| Phone | 1-858-251-4400 | Revenue | 154.90M | |
| Industry | Biotechnology | Net Income | -20,195,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 7.36% | |
| Fiscal Year-end | 12 / 2026 | Employees | 128 | |
| View SEC Filings |
HRTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.399 |
| Price to Book Ratio | 18.429 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1,391.858 |
| Enterprise Value to Sales | 2.013 |
| Total Debt to Enterprise Value | 0.451 |
HRTX Efficiency
| Revenue/Employee | 1,210,187.50 |
| Income Per Employee | -157,773.438 |
| Receivables Turnover | 1.729 |
| Total Asset Turnover | 0.343 |
HRTX Liquidity
| Current Ratio | 2.477 |
| Quick Ratio | 1.512 |
| Cash Ratio | 0.485 |
HRTX Profitability
| Gross Margin | 73.308 |
| Operating Margin | -1.638 |
| Pretax Margin | -13.037 |
| Net Margin | -13.037 |
| Return on Assets | -4.468 |
| Return on Equity | N/A |
| Return on Total Capital | -13.031 |
| Return on Invested Capital | -13.643 |
HRTX Capital Structure
| Total Debt to Total Equity | 981.218 |
| Total Debt to Total Capital | 90.751 |
| Total Debt to Total Assets | 20.963 |
| Long-Term Debt to Equity | 1,058.782 |
| Long-Term Debt to Total Capital | 90.751 |